Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Toronto
Clinical trial register · Canada

Clinical Trials in Toronto, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Canada and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6516 matching records held by the registry are in this view. Synced 02 Oct 2026, 03:18 UTC
6516
Studies in scope
all four open statuses
3504
Recruiting now
open to new participants
886
Lead sponsors
across recruiting studies
Top sites
Edmonton 38 Calgary 36 Toronto 28 Montreal 24 London 18
Narrow the registerReset
Recruitment status
Phase
Site location
Edmonton38 Calgary36 Toronto28 Montreal24 London18
All 48 locations
Target enrolment
to

Trials with a site in Toronto

28 of 6516 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Canada
Start
Recruiting
Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data
NCT07419347Hepatitis C Virus (HCV)
AbbVie
Observational
2,000
Vancouver, Toronto
2026-02-27
Active, closed
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744Ulcerative Colitis
AbbVie
Phase 3
573
Calgary, Edmonton, Barrie, Brampton, Oakville, Toronto, Montreal, Québec
2025-06-17
Active, closed
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
NCT06543914Migraine
AbbVie
Observational
1,314
Calgary, Vancouver, Saint John, Halifax, London, Ottawa, Toronto, Lévis
2024-11-26
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897Atopic Dermatitis
AbbVie
Phase 3
675
Calgary, Edmonton, Vancouver, Halifax, Hamilton, Markham, Niagara Falls, Toronto
2024-08-19
Active, closed
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643Systemic Lupus Erythematosus
AbbVie
Phase 3
1,014
Calgary, Edmonton, Winnipeg, Toronto, Sherbrooke
2023-07-25
Active, closed
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
AbbVie
Phase 3
520
Calgary, Edmonton, Surrey, Vancouver, Hamilton, Kingston, Ottawa, Toronto
2023-03-15
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
AbbVie
Phase 3
735
Calgary, Edmonton, New Westminster, Vancouver, Etobicoke, Ottawa, Toronto, Québec
2022-01-13
Active, closed
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
NCT04524611Crohn's Disease (CD)
AbbVie
Phase 3
527
Calgary, Edmonton, New Westminster, Victoria, Halifax, London, North Bay, Toronto
2020-09-30
Active, closed
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
NCT03539536Non-small Cell Lung Cancer
AbbVie
Phase 2
270
Edmonton, Ottawa, Toronto, Greenfield Park
2018-10-10
Active, closed
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
NCT02988960Advanced Solid Tumors Cancer
AbbVie
Phase 1
163
Toronto
2017-02-22
Active, closed
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
NCT02993523Acute Myeloid Leukemia (AML)
AbbVie
Phase 3
443
Calgary, Vancouver, Hamilton, Ottawa, Toronto
2017-02-02
Active, closed
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
NCT02130362Crohn's Disease
AbbVie
Observational
1,446
Edmonton, Winnipeg, Halifax, London, Toronto
2014-08-28
Rows per page Showing 1–28 of 28
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Canadian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 2 October 2026. https://priyalifescience.com/clinical-trials-canada/city/toronto

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Canada and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,516 studies in total at the last sync on 02 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 28 of those studies with a site in Toronto that also match the filters currently applied.

How many clinical trials are recruiting in Toronto?

9 of the 28 studies on this page are recruiting new participants as of the 02 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 19 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Toronto), 28 studies
PhaseStudiesRecruitingShare
Phase 313246.4%
Phase 17325%
Observational4214.3%
Phase 23110.7%
Phase 2/3113.6%

Most active sponsors

Lead sponsors with the most studies (Toronto)
Lead sponsorStudiesRecruiting
AbbVie289
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.